Targeted Therapies for Lung Cancer
This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inte
- PDF / 4,604,631 Bytes
- 244 Pages / 439.42 x 683.15 pts Page_size
- 66 Downloads / 235 Views
Ravi Salgia Editor
Targeted Therapies for Lung Cancer
Current Cancer Research
Series Editor Wafik El-Deiry
More information about this series at http://www.springer.com/series/7892
Ravi Salgia Editor
Targeted Therapies for Lung Cancer
Editor Ravi Salgia Department of Medical Oncology and Therapeutics Research City of Hope National Medical Center Duarte, CA, USA
ISSN 2199-2584 ISSN 2199-2592 (electronic) Current Cancer Research ISBN 978-3-030-17831-4 ISBN 978-3-030-17832-1 (eBook) https://doi.org/10.1007/978-3-030-17832-1 © Springer Nature Switzerland AG 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral levels. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. For example, specific mutations, genetic alterations, and overexpression of actionable targets, or immune markers, contribute to the observed heterogeneity at least in part and may potentially be exploited for delivering personalized medicine. Nonetheless, such genetic changes can be disease-specific (e.g., small-cell lung cancer versus non-small cell lung cancer) and/ or target-specific (e.g., KRAS versus EGFR). Furthermore, there are also differences in the frequency with which the genetic variants present in the patient population based on ethnic and age differences. Therefore, discerning this information i
Data Loading...